Selexis’ co-founder and scientific advisory board member will present, “Engineering the CHO Genome for Improved Transgene Integration and Expression”
(PRWeb May 20, 2013)
Read the full story at http://www.prweb.com/releases/therapeutic_protein_CHO/cell_line_development/prweb10750615.htm